Home » Newsletters » BioWorld Science

BioWorld Science

July 26, 2022

View Archived Issues

THR-beta agonists described by Shanghai Kunheng Pharmaceutical Technology, Kunming Pharmaceutical

Shanghai Institute of Materia Medica identifies new nagilactone derivatives

New SOS-1 inhibitors discovered at Chengdu Baiyu Pharmaceutical

Discovery of allosteric mutant-selective EGFR inhibitor for the treatment of NSCLC

Sarissa presents new DNA repair protein RAD51 homolog 1 inhibitors

New CDC7 inhibitors synthesized at Medshine Discovery

FDA accepts IND for HOOKIPA's arenaviral immunotherapy HB-300 for metastatic CRPC

Altamira Therapeutics to develop OligoPhore-based AM-411 for rheumatoid arthritis

PsychoGenics to evaluate preclinical antiseizure efficacy of IAMA's selective NKCC1 inhibitors

Oryzon collaborates with CMTRF to evaluate HDAC6 inhibitors for Charcot-Marie-Tooth disease

RNF31 as a novel therapeutic target for immunotherapy-refractory cancers

New compound advances anoctamin-1 inhibition for analgesia

Nonessential but critical, tyrosine plays key role in nutrient sensing

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...